Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonates
NCT01803607Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Odanacatib with Placebo (2 arms). Primary endpoint: Percent Change From Baseline to Month 12 in Femoral BMD. Started Mar 2013; status: terminated.
02
Drugs
odanacatib
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01803607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01803607.